NASDAQ$KIDS

OrthoPediatrics Corp · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

OrthoPediatrics reported Q4 2025 revenue of $61.6M with a net loss of $(10.1)M and adjusted EBITDA of $4.8M.

Q4 2025 revenue was $61.6 million (+17% YoY) with adjusted EBITDA of $4.8 million versus $3.0 million a year ago. Net loss was $(10.1) million, or $(0.43) per share. The company generated $9.8 million of free cash flow in Q4 and reiterated 2026 revenue guidance of $262M–$266M.

  • Revenue $61.6M (+17% YoY).
  • Adjusted EBITDA $4.8M.
  • Net loss $(10.1)M; EPS $(0.43).
  • Q4 free cash flow $9.8M; first positive FCF quarter.

Headline financials

Total Revenue

$61.6M

Previous: $205M-69.9%
EPS (adj)

-$0.43

Previous: -$0.29-48.3%
Adjusted EBITDA

$4.8M

Previous: $3M+60.0%
Gross Margin

73.0%

Previous: 68.0%+7.4%
Net Income

-$10.1M

Previous: -$16.1M+37.1%
Operating Income

$4.8M

Previous: -$14.1M+134.2%
Gross Profit

$45.1M

Previous: $35.6M+26.8%

Revenue & EPS history

OrthoPediatrics · Revenue · Quarterly

$61.6M

Q4 2025-69.9%vs Q4 2024
Beat estimate in 9 of 14 quarters(64%)
ActualEstimate

Revenue by segment

OrthoPediatrics · $40M total across 3 segments · Q3 2023

  • Trauma and Deformity
    $28.8M+20.5%
  • Scoliosis
    $10.3M+3.3%
  • Sports Medicine/Other
    $862K-20.1%

Forward guidance

FY 2026 revenue $262M–$266M (+11–13%); adjusted EBITDA $25M; breakeven free cash flow.

Tailwinds

  • Pediatric orthopedics share gains.
  • Cash flow inflection in Q4.

Headwinds

  • Still GAAP unprofitable.
  • New product launch execution.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-0.6%

Avg return

Earnings day

-1.0%

Avg return

5 days after

-0.4%

Avg return

30 days after

50%

17 / 34 earnings

Positive

+13.1%

Q2 2022

Best reaction

-13.0%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.8%+13.7%+14.0%
Q4 2025+8.3%+3.9%-12.8%
Q3 2025-2.6%-3.0%+9.3%
Q1 2025+4.0%+4.6%-4.5%
Q4 2024+11.9%+7.0%-0.8%
Q3 2024-7.8%-16.2%-22.3%
Q2 2024-7.8%-9.0%+3.8%
Q1 2024+5.7%-5.3%-1.9%
Q4 2023+5.4%+1.9%+0.8%
Q3 2023+4.2%-5.1%+8.9%
Q2 2023-4.6%-4.9%-7.2%
Q1 2023-7.5%-8.0%-14.4%
Q4 2022+0.5%+1.7%-0.8%
Q3 2022-13.0%-12.4%+0.8%
Q2 2022+13.1%+19.2%-0.8%
Q1 2022-10.2%-17.7%-8.1%
Q4 2021-5.8%-6.3%-2.0%
Q3 2021+2.0%+0.4%-19.4%
Q2 2021+6.9%+4.5%+9.2%
Q1 2021+10.1%+4.4%+4.4%
Q4 2020-7.1%-8.6%+2.3%
Q3 2020-6.5%+6.5%-2.1%
Q2 2020+4.7%+9.7%-0.6%
Q1 2020+2.8%+4.8%+10.0%
Q4 2019+1.1%-4.5%-19.5%
Q3 2019+5.7%+8.9%+10.6%
Q2 2019-0.2%-1.0%+10.9%
Q1 2019-9.5%-10.3%-8.3%
Q4 2018-4.3%-2.0%-6.2%
Q3 2018-12.5%-16.0%-11.4%
Q2 2018+2.7%+2.7%+23.7%
Q1 2018-1.1%+1.9%+32.0%
Q4 2017-1.9%+3.4%-2.9%
Q3 2017-11.3%-2.0%-8.5%
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016
Q1 2015

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro